Jérusalem

Entera Bio Announces Management Changes

Retrieved on: 
Monday, August 10, 2020

Dr. Garceau will continue to serve as a Director of Entera Bio.

Key Points: 
  • Dr. Garceau will continue to serve as a Director of Entera Bio.
  • Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. For more information on Entera Bio, visit www.enterabio.com .
  • There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera.
  • Entera cautions investors not to rely too heavily on the forward-looking statements Entera makes or that are made on its behalf.

Entera Bio to Present at BTIG’s Virtual Biotechnology Conference

Retrieved on: 
Wednesday, August 5, 2020

BOSTONand JERUSALEM, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its management team will participate virtually in the BTIG Biotechnology Conference onMonday, August 10, 2020at12:30 p.m. EDT.

Key Points: 
  • BOSTONand JERUSALEM, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its management team will participate virtually in the BTIG Biotechnology Conference onMonday, August 10, 2020at12:30 p.m. EDT.
  • To access a live webcast of the fireside chat on the Investor Relations page of Enteras website, please click here .
  • A replay of the webcast will be archived on Enteras website for approximately 45 days following the presentation.
  • Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. For more information on Entera Bio, visit www.enterabio.com .

Yissum Spinouts Raise $79 million in H1 2020 Despite Coronavirus Uncertainty

Retrieved on: 
Tuesday, July 28, 2020

JERUSALEM, July 28, 2020 /PRNewswire/ --Startups from The Hebrew University of Jerusalem raised $79 million in the first half of 2020, Yissum, the technology transfer company of the Hebrew University announced today.

Key Points: 
  • JERUSALEM, July 28, 2020 /PRNewswire/ --Startups from The Hebrew University of Jerusalem raised $79 million in the first half of 2020, Yissum, the technology transfer company of the Hebrew University announced today.
  • Despite the continuing global uncertainty caused by the coronavirus and ongoing lockdowns around the world, 14 Yissum spinouts raised tens of millions of dollars in early stage funding rounds.
  • Investments were made in companies in the cleantech, agriculture and foodtech sectors as well as in life science, AI and education.
  • Yissum spinouts that raised funds during in the first half of 2020 include Tissue Dynamics, an AI organ-on-chip drug development company, and Nectin Therapeutics, an immune-oncology biotech focused on cancer therapies.

Entera Bio Ltd. Announces Highly Encouraging Oral PTH Market Survey Results

Retrieved on: 
Wednesday, July 22, 2020

We believe the promising feedback from physicians currently involved in the care of high fracture risk patients with current osteoporosis medications may result in a rapid market adoption of the first oral PTH product.

Key Points: 
  • We believe the promising feedback from physicians currently involved in the care of high fracture risk patients with current osteoporosis medications may result in a rapid market adoption of the first oral PTH product.
  • Our goal is for Entera Bios EB613 oral PTH to be that product.
  • Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. For more information on Entera Bio, visit www.enterabio.com.
  • Entera cautions investors not to rely too heavily on the forward-looking statements Entera makes or that are made on its behalf.

BrainsWay to Participate in Virtual Conferences Elevate by Psych Congress Virtual Experience and Online Obsessive-Compulsive Disorder (OCD) in July 2020

Retrieved on: 
Tuesday, July 21, 2020

Online OCD Conference through July 31 - August 2.

Key Points: 
  • Online OCD Conference through July 31 - August 2.
  • It is an honor to connect with and hear from each of the communities represented at Elevate by Psych Congress and at the Online OCD Conference.
  • The treatment is medication-free, and patients can return to normal activities, such as driving, immediately following treatment.
  • BrainsWay is currently conducting clinical trials of Deep TMS in other psychiatric, neurological, and addiction disorders.

Entera Bio Ltd Provides Update on Phase 2 Clinical Trial of EB613 in Postmenopausal Women With Osteoporosis

Retrieved on: 
Tuesday, July 7, 2020

There are currently 106 patients enrolled out of the targeted 160 patients in the trial, including the new high-dose group.

Key Points: 
  • There are currently 106 patients enrolled out of the targeted 160 patients in the trial, including the new high-dose group.
  • The Phase 2 clinical trial of EB613, the Companys orally delivered PTH 1-34, is a dose-ranging, placebo-controlled, 160-patient clinical trial in postmenopausal female patients with osteoporosis, or low BMD, being conducted at four leading medical centers in Israel.
  • The Companys most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development.
  • Entera cautions investors not to rely too heavily on the forward-looking statements Entera makes or that are made on its behalf.

Orion Talent and Siemens USA Celebrate 10 Years of Continuous Success in Hiring Military Veterans

Retrieved on: 
Wednesday, June 24, 2020

Orion Talent , a provider of best-in-class military hiring and talent optimization solutions, proudly announced the 10-year anniversary of its Talent Program with Siemens USA to recruit, train, and retain skilled transitioning military service members and veterans.

Key Points: 
  • Orion Talent , a provider of best-in-class military hiring and talent optimization solutions, proudly announced the 10-year anniversary of its Talent Program with Siemens USA to recruit, train, and retain skilled transitioning military service members and veterans.
  • To date, the carefully crafted program has resulted in a continuous pipeline of high caliber military talent and a retention rate that far surpasses the market norm.
  • Since launching its military hiring program, Siemens has recruited nearly 4,000 service members from all four branches of the U.S. Military: Air Force, Navy, Army, and Marine Corps.
  • We do this by providing best-in-class military hiring and talent solutions which include RPO, Military Talent Solutions, Candidate Search, Talent Attraction, and Total Talent Solutions.

BrainsWay Launches New Website to Enhance Mental Health Awareness

Retrieved on: 
Tuesday, June 16, 2020

The new site features a modern and user-friendly layout, with easy access to mental health resources for both patients and healthcare professionals.

Key Points: 
  • The new site features a modern and user-friendly layout, with easy access to mental health resources for both patients and healthcare professionals.
  • Our nation is on the verge of a mental health crisis as a consequence of the coronavirus pandemic.
  • It is critical, now more than ever, to ensure that patients and doctors have easy access to accurate and reliable information on mental illness and its treatments.
  • BrainsWay is committed to raising awareness and providing education around mental health, specifically for those with major depressive disorder and obsessive-compulsive disorder (OCD), for which Deep Transcranial Magnetic Stimulation (Deep TMS) is FDA cleared.

BrainsWay to Report First Quarter 2020 Financial Results and Operational Highlights on June 24, 2020

Retrieved on: 
Tuesday, June 9, 2020

PATTERSON, N.J. and JERUSALEM, Israel, June 09, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced non-invasive treatment of brain disorders, today announced that it will report its first quarter 2020 financial results and operational highlights on June 24, 2020.

Key Points: 
  • PATTERSON, N.J. and JERUSALEM, Israel, June 09, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced non-invasive treatment of brain disorders, today announced that it will report its first quarter 2020 financial results and operational highlights on June 24, 2020.
  • The Company will host a conference call at 8:30 AM Eastern Time to review the financial results and operational highlights.
  • The conference call will be broadcast live and will be available for replay for 30 days on the Company's website, https://investors.brainsway.com/financial-calendar .
  • BrainsWay is currently conducting clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders.